Literature DB >> 25819947

Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus.

Juliane Redecker1, Matthias Wittstock2, Reiner Benecke3, Johannes Rösche4.   

Abstract

We provide some evidence concerning the efficacy of perampanel (PER) in refractory status epilepticus (SE). We retroactively identified patients with SE treated in our department by searching for the term "status epilepticus" in the electronic archive of medical records. We present and analyze in this paper the subset of data of the patients treated with PER. We analyzed ten episodes of SE in nine patients. At the first administration, PER was given in a dosage of 6mg to most of our patients (7 of 10). On average, PER was administered as the 6th antiepileptic drug (AED) (range: 2-10). Depending on the criterion for efficacy, PER appears effective for the termination of SE in 2 to 6 (of 10) episodes. Unfortunately, safety data for the administration of PER with loading doses needed for the treatment of SE are lacking. Because of this, PER should be used very carefully in refractory SE and only after first-line treatment options have failed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Criteria of efficacy; Nonconvulsive status epilepticus; Perampanel

Mesh:

Substances:

Year:  2015        PMID: 25819947     DOI: 10.1016/j.yebeh.2015.01.036

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  11 in total

1.  [Perampanel as a therapy option in patients with epilepsy].

Authors:  M Hintz; S Nawratil; A Schulze-Bonhage
Journal:  Nervenarzt       Date:  2016-08       Impact factor: 1.214

2.  Treatment of Convulsive Status Epilepticus.

Authors:  Eric H Grover; Yara Nazzal; Lawrence J Hirsch
Journal:  Curr Treat Options Neurol       Date:  2016-03       Impact factor: 3.598

Review 3.  Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults.

Authors:  Martin Holtkamp
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 4.  Antiseizure medications in critical care: an update.

Authors:  Baxter Allen; Paul M Vespa
Journal:  Curr Opin Crit Care       Date:  2019-04       Impact factor: 3.687

5.  Perampanel reduces paroxysmal depolarizing shift and inhibitory synaptic input in excitatory neurons to inhibit epileptic network oscillations.

Authors:  Ya-Chin Yang; Guan-Hsun Wang; Ai-Yu Chuang; Shu-Wei Hsueh
Journal:  Br J Pharmacol       Date:  2020-09-28       Impact factor: 8.739

6.  Enhanced AMPA receptor-mediated neurotransmission on CA1 pyramidal neurons during status epilepticus.

Authors:  Suchitra Joshi; Karthik Rajasekaran; Huayu Sun; John Williamson; Jaideep Kapur
Journal:  Neurobiol Dis       Date:  2017-04-02       Impact factor: 5.996

7.  Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review.

Authors:  Siew-Na Lim; Tony Wu; Wei-En Johnny Tseng; Hsing-I Chiang; Mei-Yun Cheng; Wey-Ran Lin; Chia-Ni Lin
Journal:  J Neurol       Date:  2021-03-22       Impact factor: 4.849

Review 8.  Newer Antiepileptic Drugs for Status Epilepticus in Adults: What's the Evidence?

Authors:  Isabelle Beuchat; Jan Novy; Andrea O Rossetti
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

9.  Perampanel for Refractory Status Epilepticus… Another Tool in the Armamentarium.

Authors:  Sara Hocker
Journal:  Neurocrit Care       Date:  2019-08       Impact factor: 3.210

10.  Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain.

Authors:  Adam Strzelczyk; Susanne Knake; Reetta Kälviäinen; Estevo Santamarina; Manuel Toledo; Sophia Willig; Alexandra Rohracher; Eugen Trinka; Felix Rosenow
Journal:  Acta Neurol Scand       Date:  2019-01-20       Impact factor: 3.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.